Tag: BioNTech

In a year marked by significant revenue declines for major players in the mRNA and COVID-19 vaccine space, BioNTech SE ...

BioNTech's stock has faced significant headwinds from founder transitions and subdued financial forecasts. However, developments within its research pipeline offer ...

Following a period of significant pressure after its founders announced their departure, BioNTech is shifting investor focus back to its ...

The European Lung Cancer Congress in Copenhagen, which opens today, serves as a critical platform for BioNTech to showcase its ...

The investment narrative surrounding BioNTech is currently being shaped by a confluence of challenges. Despite the company's strategic moves to ...

The year 2026 is shaping up to be a decisive period for BioNTech as it seeks to solidify its transition ...

The future trajectory of BioNTech SE is becoming increasingly tied to a single, promising oncology asset. The company’s ambitious cancer ...

A significant strategic transition is underway at Mainz-based biotechnology firm BioNTech. While news of the impending departure of its two ...

The German biotech firm BioNTech is navigating its most significant transition since the peak of the pandemic. Co-founders Ugur Sahin ...

The German biotech firm BioNTech is navigating its most significant strategic transition to date. Two concurrent developments have unsettled the ...